MARKET WIREReuters • 1h ago
China's foreign minister pushes for dialogue to resolve Middle East conflict - ReutersChina's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
Why TVGN Stock dropped -2.48% Today — RQD Quant Desk Flash
$5.90 -2.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.86
Tevogen Inc. (TVGN) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $95.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TVGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TVGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Tevogen Inc. (NASDAQ: TVGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $5.90 (-2.48% 1D, market cap $95.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TVGN ranks #530 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TVGN compare to TNYA and ENGN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TVGN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TNYA (Tenaya Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $90.8M) and ENGN (enGene Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M). Among the 5-stock peer group, TVGN leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TVGN?
▼
Per TVGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860871), Tevogen Inc. generated $0 in revenue, -$26.3M in net income, and -$12.4M in free cash flow against $4.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.86 (-0.64%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TVGN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY TVGN SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (30% of score)
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 37.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$6.78+4.3% Next Q
48
Q2 (-2Q)Grade D$7.07-7.6% Next Q
45
Q3 (-1Q)Grade D$6.53-9.6% Next Q
43
CurrentGrade D-$5.90-7.4% Hist 90D α
40
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TVGN Turnaround Squeeze
While TVGN currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.97) and Max Pain ($6.20) forces dealer call-delta covering toward $34.13.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TVGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TVGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TVGN Stock dropped -2.48% Today — RQD Quant Desk Flash
Tevogen Inc. (TVGN) dropped -2.48% to $5.90, trading at 8% of its 52-week range ($3.64 – $32.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 8% of its 52-week range ($3.64 – $32.5) with RSI-14 at 37.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TVGN Headlines & Catalysts
MARKET WIREReuters • 1h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 1h ago
US voters in a sour economic mood heading into midterm elections - ReutersUS voters in a sour economic mood heading into midterm elections Reuters
MARKET WIREReuters • 2h ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
MARKET WIREReuters • 5h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 6h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 7h ago
Gold rebounds from one-year low as oil slides ahead of US midterms - ReutersGold rebounds from one-year low as oil slides ahead of US midterms Reuters
MARKET WIREReuters • 8h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TVGN)
- ✓Walkthrough of TVGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TVGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.14%🛡️ HOLDING TREND SUPPORT
2026-10-30O $5.95H $6.32L $5.80C $5.90VOL 3.0K
RES: $8.46SUP: $5.86SMA50: $6.97SMA200: $8.19
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TVGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TVGN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TVGN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TVGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TVGN)
Health Care Rank #530 of 1016
⚔️ TNYA vs TVGN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TVGN vs. TNYA, ENGN, ATRA, BDTX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Tevogen Inc. (TVGN) ranks #530 by composite RQD confidence (40/100, grade D-) and #666 by equity capitalization ($95.2M). Within this direct 5-issuer industry benchmark cohort, TVGN leads on earnings valuation at N/A trailing P/E, while ATRA leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BDTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with TVGN at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TVGN
ACTIVE
Tevogen Inc. | D- | 40/100 | — | — | -35.0% | -2.48% | $95.2M | Benchmark Subject |
| TNYA Tenaya Therapeutics Inc. | D | 46/100 | — | — | -35.0% | -7.78% | $90.8M | /tnya-vs-tvgn → |
| ENGN enGene Therapeutics Inc. | E | 34/100 | — | — | -35.0% | 0.00% | $102.5M | /engn-vs-tvgn → |
| ATRA Atara Biotherapeutics Inc. | D+ | 54/100 | — | — | 85.0% | -6.10% | $85.6M | /atra-vs-tvgn → |
| BDTX Black Diamond Therapeutics Inc. | C- | 59/100 | — | — | 10.8% | -4.30% | $106.9M | /bdtx-vs-tvgn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001860871In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tevogen Inc. (TVGN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.3M, operating cash flow of -$12.3M, and free cash flow of -$12.4M (-3.3% YoY). On the balance sheet, TVGN closed FY2025 with $4.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$26.3M | -$12.3M | -$12.4M | $4.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$13.7M | -$12.0M | -$12.0M | $3.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$60.5M | -$8.2M | -$8.2M | — | — |
3. TVGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TVGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Tevogen Inc. (NASDAQ: TVGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $5.90 (-2.48% 1D, market cap $95.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TVGN ranks #530 in composite RQD confidence.
How does TVGN compare to TNYA and ENGN in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TVGN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TNYA (Tenaya Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $90.8M) and ENGN (enGene Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M). Among the 5-stock peer group, TVGN leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TVGN?
Per TVGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860871), Tevogen Inc. generated $0 in revenue, -$26.3M in net income, and -$12.4M in free cash flow against $4.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TVGN trading relative to its 50-day, 200-day, and 52-week technical levels?
TVGN last traded at $5.90 (-2.48% on volume of 2,996 shares), positioning the stock -15.35% below its 50-day simple moving average ($6.97) and -27.96% below its 200-day simple moving average ($8.19). Across its 52-week range of $3.64 to $32.50, TVGN sits at the 7.8% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.16 to $6.64).
TVGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TVGN stock moving today?
Why TVGN Stock dropped -2.48% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.